Summary
973.45 5.45(0.56%)05/10/2024
Regeneron Pharmaceuticals, Inc. (REGN)
Regeneron Pharmaceuticals, Inc. (REGN)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 1.20 | 8.81 | 3.30 | 3.24 | 16.70 | 28.91 | 200.72 | 4,488.41 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 969.53 | |
| Open | 967.88 | |
| High | 969.60 | |
| Low | 957.10 | |
| Volume | 271,308 | |
| Change | 11.47 | |
| Change % | 1.20 | |
| Avg Volume (20 Days) | 377,438 | |
| Volume/Avg Volume (20 Days) Ratio | 0.72 | |
| 52 Week Range | 684.81 - 998.32 | |
| Price vs 52 Week High | -2.88% | |
| Price vs 52 Week Low | 41.58% | |
| Range | 0.17 | |
| Gap Up/Down | 5.78 | |
Fundamentals | ||
| Market Capitalization (Mln) | 106,660 | |
| EBIDTA | 4,424,500,224 | |
| PE Ratio | 28.5714 | |
| PEG Ratio | 1.4591 | |
| WallStreet Target Price | 1,053.60 | |
| Book Value | 250.1490 | |
| Earnings Per Share | 33.8800 | |
| EPS Estimate Current Quarter | 10.0900 | |
| EPS Estimate Next Quarter | 10.8900 | |
| EPS Estimate Current Year | 44.2400 | |
| EPS Estimate Next Year | 47.9600 | |
| Diluted EPS (TTM) | 33.8800 | |
| Revenues | ||
| Profit Marging | 0.2945 | |
| Operating Marging (TTM) | 0.2412 | |
| Return on asset (TTM) | 0.0774 | |
| Return on equity (TTM) | 0.1528 | |
| Revenue TTM | 13,100,099,584 | |
| Revenue per share TTM | 122.5740 | |
| Quarterly Revenue Growth (YOY) | -0.0050 | |
| Quarterly Earnings Growth (YOY) | -0.1260 | |
| Gross Profit (TTM) | 7,020,000,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 28.5714 | |
| Forward PE | 20.1207 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 3.8232 | |
| Revenue Enterprise Value | 6.9495 | |
| EBITDA Enterprise Value | 19.4231 | |
| Shares | ||
| Shares Outstanding | 108,367,000 | |
| Shares Float | 103,291,738 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.02 | |
| Insider (%) | 1.69 | |
| Institutions (%) | 89.04 | |
05/10 07:24 EST - MarketBeat
Will the Biotech Sector Shift From Lagger to Leader?
The biotech sector and its popular ETF, the iShares Biotechnology ETF NASDAQ: IBB, have lagged the overall market during the year, with its shares slightly red. However, in recent weeks, the sector has enjoyed a significant rally after bouncing off its uptrend support and now consolidating near several major Simple Moving Averages (SMA).
Will the Biotech Sector Shift From Lagger to Leader?
The biotech sector and its popular ETF, the iShares Biotechnology ETF NASDAQ: IBB, have lagged the overall market during the year, with its shares slightly red. However, in recent weeks, the sector has enjoyed a significant rally after bouncing off its uptrend support and now consolidating near several major Simple Moving Averages (SMA).
05/08 06:11 EST - Reuters
Regeneron's experimental gene therapy improves hearing in one patient
Regeneron Pharmaceuticals said on Wednesday its investigational gene therapy improved hearing to normal levels in a child within 24 weeks in an early to mid-stage study.
Regeneron's experimental gene therapy improves hearing in one patient
Regeneron Pharmaceuticals said on Wednesday its investigational gene therapy improved hearing to normal levels in a child within 24 weeks in an early to mid-stage study.
05/04 12:00 EST - InvestorPlace
3 Biotech Stocks With the Potential to Make You an Overnight Millionaire
Biotechnology offers breakthrough drugs and treatments that open new doors in the field of medicine. Companies are releasing more drugs and developing state-of-the-art methods to treat previously untreatable conditions.
3 Biotech Stocks With the Potential to Make You an Overnight Millionaire
Biotechnology offers breakthrough drugs and treatments that open new doors in the field of medicine. Companies are releasing more drugs and developing state-of-the-art methods to treat previously untreatable conditions.
05/03 06:15 EST - InvestorPlace
Shhh! 3 Secret Pharma Stocks Flying Below Wall Street's Radar
Pharma stocks and massive potential go hand in hand. With devastating diseases like cancer, diabetes and heart disease still far from finding a cure, drugs that treat these conditions often command exorbitant prices.
Shhh! 3 Secret Pharma Stocks Flying Below Wall Street's Radar
Pharma stocks and massive potential go hand in hand. With devastating diseases like cancer, diabetes and heart disease still far from finding a cure, drugs that treat these conditions often command exorbitant prices.
05/02 11:06 EST - Zacks Investment Research
Regeneron (REGN) Q1 Earnings, Sales Miss on Lower Eylea Sales
Regeneron (REGN) reports Q1 results, wherein both the top and bottom lines miss estimates due to lower Eylea sales. Shares down.
Regeneron (REGN) Q1 Earnings, Sales Miss on Lower Eylea Sales
Regeneron (REGN) reports Q1 results, wherein both the top and bottom lines miss estimates due to lower Eylea sales. Shares down.
05/02 10:36 EST - Zacks Investment Research
Regeneron (REGN) Reports Q1 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Regeneron (REGN) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Regeneron (REGN) Reports Q1 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Regeneron (REGN) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
05/02 06:45 EST - Market Watch
Regeneron's stock dips after earnings fall short of estimates
Regeneron Pharmaceuticals Inc.'s stock REGN, +1.44% fell 3% early Thursday, after the company's first-quarter earnings fell short of estimates. The company had net income of $722 million, or $6.27 a share, in the quarter, down 12% from $818 million, or $7.17 a share, in the year-earlier period.
Regeneron's stock dips after earnings fall short of estimates
Regeneron Pharmaceuticals Inc.'s stock REGN, +1.44% fell 3% early Thursday, after the company's first-quarter earnings fell short of estimates. The company had net income of $722 million, or $6.27 a share, in the quarter, down 12% from $818 million, or $7.17 a share, in the year-earlier period.
05/02 06:39 EST - Reuters
Regeneron misses profit estimates on weaker Eylea and Dupixent sales
U.S. drugmaker Regeneron Pharmaceuticals Inc missed Wall Street estimates for first-quarter profit on Thursday due to softer sales of its blockbuster eye drug Eylea and its eczema treatment, Dupixent.
Regeneron misses profit estimates on weaker Eylea and Dupixent sales
U.S. drugmaker Regeneron Pharmaceuticals Inc missed Wall Street estimates for first-quarter profit on Thursday due to softer sales of its blockbuster eye drug Eylea and its eczema treatment, Dupixent.
04/30 12:21 EST - Zacks Investment Research
Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?
Let's look at five large-cap pharma/biotech companies slated to release quarterly results this week.
Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?
Let's look at five large-cap pharma/biotech companies slated to release quarterly results this week.
04/30 09:50 EST - Zacks Investment Research
Should You Consider Regeneron (REGN) Ahead of Q1 Earnings?
An increase in profits from Dupixent and further uptake of Eylea HD are likely to have aided Regeneron (REGN) in partially offsetting the decline in Eylea sales.
Should You Consider Regeneron (REGN) Ahead of Q1 Earnings?
An increase in profits from Dupixent and further uptake of Eylea HD are likely to have aided Regeneron (REGN) in partially offsetting the decline in Eylea sales.
04/29 10:36 EST - Zacks Investment Research
Down -8.24% in 4 Weeks, Here's Why Regeneron (REGN) Looks Ripe for a Turnaround
Regeneron (REGN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Down -8.24% in 4 Weeks, Here's Why Regeneron (REGN) Looks Ripe for a Turnaround
Regeneron (REGN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
04/29 10:22 EST - Zacks Investment Research
Countdown to Regeneron (REGN) Q1 Earnings: A Look at Estimates Beyond Revenue and EPS
Evaluate the expected performance of Regeneron (REGN) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Countdown to Regeneron (REGN) Q1 Earnings: A Look at Estimates Beyond Revenue and EPS
Evaluate the expected performance of Regeneron (REGN) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
04/25 12:45 EST - Zacks Investment Research
EXEL vs. REGN: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Exelixis (EXEL) and Regeneron (REGN). But which of these two stocks is more attractive to value investors?
EXEL vs. REGN: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Exelixis (EXEL) and Regeneron (REGN). But which of these two stocks is more attractive to value investors?
04/25 08:48 EST - Reuters
AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study
AbbVie said on Thursday its drug, Rinvoq, for treating a type of inflammatory skin condition was found to be more effective than Regeneron Pharmaceuticals and Sanofi's Dupixent in a late-stage head-to-head study.
AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study
AbbVie said on Thursday its drug, Rinvoq, for treating a type of inflammatory skin condition was found to be more effective than Regeneron Pharmaceuticals and Sanofi's Dupixent in a late-stage head-to-head study.
04/25 07:14 EST - Reuters
Regeneron to collaborate on gene editing therapies with Doudna-founded Mammoth
Regeneron Pharmaceuticals and Mammoth Biosciences will collaborate to research, develop and commercialize gene editing therapies for multiple diseases, the companies said on Thursday.
Regeneron to collaborate on gene editing therapies with Doudna-founded Mammoth
Regeneron Pharmaceuticals and Mammoth Biosciences will collaborate to research, develop and commercialize gene editing therapies for multiple diseases, the companies said on Thursday.
04/17 09:51 EST - Zacks Investment Research
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
04/16 13:16 EST - Zacks Investment Research
Why Regeneron (REGN) Could Beat Earnings Estimates Again
Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why Regeneron (REGN) Could Beat Earnings Estimates Again
Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
04/15 19:24 EST - Reuters
Regeneron to defend US Justice Department's complaint on drug-pricing manipulation
Regeneron Pharmaceuticals said on Monday the U.S. Justice Department's complaint against the company misreporting the average sales price for its macular degeneration drug Eylea is "meritless" and it plans to defend this case in court.
Regeneron to defend US Justice Department's complaint on drug-pricing manipulation
Regeneron Pharmaceuticals said on Monday the U.S. Justice Department's complaint against the company misreporting the average sales price for its macular degeneration drug Eylea is "meritless" and it plans to defend this case in court.
04/12 14:56 EST - Zacks Investment Research
Regeneron (REGN) Accused of Fraudulent Practices Related to Eylea
The U.S. Department of Justice files a complaint against Regeneron (REGN), alleging fraudulent drug pricing practices related to its lead drug, Eylea.
Regeneron (REGN) Accused of Fraudulent Practices Related to Eylea
The U.S. Department of Justice files a complaint against Regeneron (REGN), alleging fraudulent drug pricing practices related to its lead drug, Eylea.
04/11 08:25 EST - Investopedia
Regeneron Stock Under Microscope After DOJ Price Reporting Complaint—Key Levels to Watch
Shares in biotech giant Regeneron Pharmaceuticals (REGN) go under the microscope Thursday after the U.S. Department of Justice (DOJ) accused the company of manipulating Medicare's drug pricing reporting by inflating the average sales price of its best-selling eye disease drug Eylea.
Regeneron Stock Under Microscope After DOJ Price Reporting Complaint—Key Levels to Watch
Shares in biotech giant Regeneron Pharmaceuticals (REGN) go under the microscope Thursday after the U.S. Department of Justice (DOJ) accused the company of manipulating Medicare's drug pricing reporting by inflating the average sales price of its best-selling eye disease drug Eylea.